JP2024109765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024109765A5 JP2024109765A5 JP2024083009A JP2024083009A JP2024109765A5 JP 2024109765 A5 JP2024109765 A5 JP 2024109765A5 JP 2024083009 A JP2024083009 A JP 2024083009A JP 2024083009 A JP2024083009 A JP 2024083009A JP 2024109765 A5 JP2024109765 A5 JP 2024109765A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- unsubstituted
- independently selected
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782298P | 2018-12-19 | 2018-12-19 | |
| US62/782,298 | 2018-12-19 | ||
| US201962879900P | 2019-07-29 | 2019-07-29 | |
| US62/879,900 | 2019-07-29 | ||
| PCT/US2019/067088 WO2020132014A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| JP2021535539A JP7494181B2 (ja) | 2018-12-19 | 2019-12-18 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535539A Division JP7494181B2 (ja) | 2018-12-19 | 2019-12-18 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024109765A JP2024109765A (ja) | 2024-08-14 |
| JP2024109765A5 true JP2024109765A5 (https=) | 2024-11-13 |
| JP7724911B2 JP7724911B2 (ja) | 2025-08-18 |
Family
ID=71098067
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535539A Active JP7494181B2 (ja) | 2018-12-19 | 2019-12-18 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
| JP2024083009A Active JP7724911B2 (ja) | 2018-12-19 | 2024-05-22 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535539A Active JP7494181B2 (ja) | 2018-12-19 | 2019-12-18 | 置換３－（（３－アミノフェニル）アミノ）ピペリジン－２，６－ジオン化合物、その組成物、及びそれを用いた治療方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US11149007B2 (https=) |
| EP (2) | EP4494711A3 (https=) |
| JP (2) | JP7494181B2 (https=) |
| KR (2) | KR102866144B1 (https=) |
| CN (2) | CN113453681B (https=) |
| AU (1) | AU2019403207B2 (https=) |
| BR (1) | BR112021011968A2 (https=) |
| CA (1) | CA3124130A1 (https=) |
| CL (1) | CL2021001665A1 (https=) |
| CO (1) | CO2021007973A2 (https=) |
| DK (1) | DK3897636T3 (https=) |
| ES (1) | ES3009308T3 (https=) |
| FI (1) | FI3897636T3 (https=) |
| HR (1) | HRP20250095T1 (https=) |
| HU (1) | HUE070506T2 (https=) |
| IL (1) | IL284223B2 (https=) |
| LT (1) | LT3897636T (https=) |
| MX (1) | MX2021007473A (https=) |
| MY (1) | MY205718A (https=) |
| PE (1) | PE20212247A1 (https=) |
| PL (1) | PL3897636T3 (https=) |
| PT (1) | PT3897636T (https=) |
| RS (1) | RS66556B1 (https=) |
| SG (1) | SG11202106507RA (https=) |
| SI (1) | SI3897636T1 (https=) |
| SM (1) | SMT202500111T1 (https=) |
| TW (1) | TWI820276B (https=) |
| WO (1) | WO2020132014A1 (https=) |
| ZA (1) | ZA202104200B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| CN113453681B (zh) * | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| KR20230027066A (ko) * | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| JP7778095B2 (ja) * | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| AU2021311245A1 (en) * | 2020-07-21 | 2023-03-09 | Ubix Therapeutics, Inc. | Compound for androgen receptor degradation, and pharmaceutical use thereof |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN117203196A (zh) | 2020-12-14 | 2023-12-08 | 拜欧斯瑞克斯公司 | Pde4降解剂、药物组合物和治疗应用 |
| BR112023018839A2 (pt) * | 2021-03-17 | 2023-12-26 | Medshine Discovery Inc | Composto de glutarimida substituído por anel fundido com furano |
| KR20240026946A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| WO2022272061A1 (en) * | 2021-06-25 | 2022-12-29 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| CN117561249A (zh) * | 2021-06-25 | 2024-02-13 | 细胞基因公司 | Cereblon结合化合物、其组合物及其用于治疗的方法 |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| CN120152718A (zh) * | 2022-11-09 | 2025-06-13 | 百时美施贵宝公司 | 用取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物的组合疗法 |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
| WO2025235600A1 (en) * | 2024-05-07 | 2025-11-13 | Bristol-Myers Squibb Company | Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds |
| WO2025235577A1 (en) | 2024-05-09 | 2025-11-13 | Bristol-Myers Squibb Company | Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds |
| CN118993935B (zh) * | 2024-10-23 | 2025-02-14 | 江苏恒瑞医药股份有限公司 | 咪唑啉衍生物或其盐的制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| FR2768728B1 (fr) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique |
| FR2768729A1 (fr) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique et complexes catalytiques |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US8470829B2 (en) * | 2004-09-09 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Imidazolidine derivative and use thereof |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| EP2683694B1 (en) * | 2011-03-10 | 2016-04-27 | Suzhou Kintor Pharmaceuticals, Inc. | Androgen receptor antagonists and uses thereof |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014036897A1 (zh) * | 2012-09-04 | 2014-03-13 | 上海恒瑞医药有限公司 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RU2683788C2 (ru) | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110167556A (zh) | 2016-07-08 | 2019-08-23 | 詹森药业有限公司 | 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂 |
| TWI739888B (zh) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | 農藥組合物及方法 |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| US10925868B2 (en) | 2016-11-10 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| AU2017378943B2 (en) | 2016-12-19 | 2020-06-18 | Abbisko Therapeutics Co., Ltd. | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109422725A (zh) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| ES2959954T3 (es) | 2017-11-28 | 2024-02-29 | Aarti Pharmalabs Ltd | Proceso para la preparación de enzalutamida utilizando un nuevo intermedio |
| EP3720281A4 (en) | 2017-12-05 | 2021-05-26 | Dow Agrosciences LLC | PESTICIDE COMPOSITIONS AND PROCEDURES |
| CN114835729B (zh) | 2018-05-30 | 2024-05-31 | 江苏豪森药业集团有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
| CN109651256A (zh) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN113453681B (zh) * | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
-
2019
- 2019-12-18 CN CN201980092358.2A patent/CN113453681B/zh active Active
- 2019-12-18 PE PE2021000924A patent/PE20212247A1/es unknown
- 2019-12-18 RS RS20250148A patent/RS66556B1/sr unknown
- 2019-12-18 BR BR112021011968-0A patent/BR112021011968A2/pt unknown
- 2019-12-18 HU HUE19901383A patent/HUE070506T2/hu unknown
- 2019-12-18 DK DK19901383.0T patent/DK3897636T3/da active
- 2019-12-18 MX MX2021007473A patent/MX2021007473A/es unknown
- 2019-12-18 CN CN202411325996.3A patent/CN119219606A/zh active Pending
- 2019-12-18 WO PCT/US2019/067088 patent/WO2020132014A1/en not_active Ceased
- 2019-12-18 ES ES19901383T patent/ES3009308T3/es active Active
- 2019-12-18 AU AU2019403207A patent/AU2019403207B2/en active Active
- 2019-12-18 PT PT199013830T patent/PT3897636T/pt unknown
- 2019-12-18 CA CA3124130A patent/CA3124130A1/en active Pending
- 2019-12-18 LT LTEPPCT/US2019/067088T patent/LT3897636T/lt unknown
- 2019-12-18 SM SM20250111T patent/SMT202500111T1/it unknown
- 2019-12-18 FI FIEP19901383.0T patent/FI3897636T3/fi active
- 2019-12-18 TW TW108146514A patent/TWI820276B/zh active
- 2019-12-18 EP EP24218737.5A patent/EP4494711A3/en active Pending
- 2019-12-18 KR KR1020217019479A patent/KR102866144B1/ko active Active
- 2019-12-18 IL IL284223A patent/IL284223B2/en unknown
- 2019-12-18 MY MYPI2021003454A patent/MY205718A/en unknown
- 2019-12-18 US US16/719,171 patent/US11149007B2/en active Active
- 2019-12-18 EP EP19901383.0A patent/EP3897636B1/en active Active
- 2019-12-18 SG SG11202106507RA patent/SG11202106507RA/en unknown
- 2019-12-18 HR HRP20250095TT patent/HRP20250095T1/hr unknown
- 2019-12-18 JP JP2021535539A patent/JP7494181B2/ja active Active
- 2019-12-18 PL PL19901383.0T patent/PL3897636T3/pl unknown
- 2019-12-18 KR KR1020257032139A patent/KR20250144505A/ko active Pending
- 2019-12-18 SI SI201930889T patent/SI3897636T1/sl unknown
-
2021
- 2021-06-18 ZA ZA2021/04200A patent/ZA202104200B/en unknown
- 2021-06-18 CL CL2021001665A patent/CL2021001665A1/es unknown
- 2021-06-18 CO CONC2021/0007973A patent/CO2021007973A2/es unknown
- 2021-08-16 US US17/403,742 patent/US11873283B2/en active Active
-
2023
- 2023-11-28 US US18/521,663 patent/US12404241B2/en active Active
-
2024
- 2024-05-22 JP JP2024083009A patent/JP7724911B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024109765A5 (https=) | ||
| JP2022514347A5 (https=) | ||
| JP2024071370A5 (https=) | ||
| JP2022512482A5 (https=) | ||
| JP2023531709A5 (https=) | ||
| JP2023126440A5 (https=) | ||
| JP2019031560A5 (https=) | ||
| JP2024520481A5 (https=) | ||
| JP2023533203A5 (https=) | ||
| KR101454571B1 (ko) | 트레프로스티닐 생산을 위한 중간체 합성 | |
| JP2022520448A5 (https=) | ||
| JP2022544714A5 (https=) | ||
| JP2018115215A5 (https=) | ||
| JP2018531982A5 (https=) | ||
| EP2788351A1 (en) | SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS | |
| JP2024534014A5 (https=) | ||
| RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
| JP2023531495A5 (https=) | ||
| JP2022507251A5 (https=) | ||
| JP2020097596A5 (https=) | ||
| CN110770233A (zh) | 稠合双环类化合物及其在药物中的应用 | |
| JP2022504620A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2007522142A5 (https=) | ||
| CN111655678A (zh) | 细胞凋亡信号调节激酶-1抑制剂及其应用 |